A5004140332- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Angiogenesis and VEGF in Cancer
- Multiple Myeloma Research and Treatments
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Multiple and Secondary Primary Cancers
- Hepatocellular Carcinoma Treatment and Prognosis
- Vitamin D Research Studies
- Sexual Differentiation and Disorders
- Bladder and Urothelial Cancer Treatments
- Cancer Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Radiopharmaceutical Chemistry and Applications
- Estrogen and related hormone effects
NHS Tayside
2025
Ninewells Hospital
2025
Beatson West of Scotland Cancer Centre
2015-2024
University Hospital Ayr
2022
NHS Greater Glasgow and Clyde
2020
Wishaw General Hospital
2015
NHS Ayrshire and Arran
2012
King Faisal Specialist Hospital & Research Centre
2012
Cancer Research UK Scotland Institute
2006-2011
Switch
2008
Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) programmed cell death ligand-1 (PD-L1) inhibition in this disease. In study, the combination of savolitinib (MET inhibitor) durvalumab (PD-L1 investigated.This single-arm phase II trial explored (1,500 mg once every four weeks) (600 daily; ClinicalTrials.gov identifier: NCT02819596). Treatment-naïve or...
BackgroundAbiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed evaluate long-term and test whether combining abiraterone survival.MethodsWe analysed two open-label, randomised, controlled, phase 3 trials STAMPEDE platform protocol, no overlapping controls, conducted 117 sites in UK Switzerland. Eligible (no age restriction) had...
Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation vital. The Trial Imaging and Surveillance Seminoma Testis (TRISST) assessed whether magnetic resonance images (MRIs) or a reduced scan schedule could be used without unacceptable increase advanced relapses.A phase III, noninferiority, factorial trial. Eligible participants had undergone orchiectomy...
Abstract Background E7080 is an orally active multi-targeted kinase inhibitor whose targets include vascular endothelial growth factor receptors (VEGFR), fibroblast receptor (FGFR) and platelet derived (PDGFR). It has been shown to inhibit tumor angiogenesis by targeting cells. A number of the are also expressed on cells here we have looked at direct effects cell behavior. Methods Using a panel human lines determined effect proliferation, migration invasion. Inhibition FGFR PDGFR signaling...
545 Background: Metastatic papillary renal cancer (PRC) has poor outcomes and there is need for new treatments. There a strong rationale investigating MET PD-L1 inhibition in this disease. In study, we investigate savolitinib (MET inhibitor) durvalumab (PD-L1 together. Methods: This single arm phase I/II trial explored at starting doses of 1500mg Q4W 600mg OD respectively, with 4wk run-in. Treatment naïve or previously treated patients metastatic PRC were included. Response rate (RR) (RECIST...
The analysis demonstrated that the starting dose of lenvatinib 14 mg is not noninferior to 18 (both with everolimus). Safety profiles were similar in both arms. Findings support + everolimus 5 for patients advanced renal cell carcinoma. Lenvatinib (18 mg) plus (5 approved carcinoma (RCC) after one or more prior antiangiogenic therapies. To assess whether a lower has comparable efficacy improved tolerability RCC treated everolimus. A randomized, open-label, phase 2 global trial was conducted...
83 Background: Darolutamide has authorisation for treatment of non-metastatic Castrate Resistant Prostate Cancer (nmCRPC) based on the ARAMIS trial. The RECORD Study is a prospective real-world evaluation (RWE) clinical outcomes in patients with nmCRPC treated darolutamide UK. study will improve understanding response and duration as well inform regarding use next generation imaging (NGI) effects concomitant medication. Methods: Patients were enrolled from 19 centres over 3-year period...
To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) first year use outside a clinical trial.Patients West Scotland Cancer Network with newly diagnosed mPC were identified from regional multidisciplinary team meetings their treatment details collected electronic patient records. The rate febrile neutropenia, hospitalisations, time to progression, overall survival compared between those patients who received...
Abstract Purpose: OSI-7904L is a liposomal formulation of potent noncompetitive thymidylate synthase inhibitor (TSI) that does not require polyglutamation for activity. This phase I study was done to establish the safety, tolerability, maximum tolerated dose, recommended and pharmacokinetics in patients with advanced solid tumors refractory standard therapy. Design: given as 30-minute i.v. infusion every 21 days 31 at eight dose levels from 0.4 15.0 mg/m2, using three per level, up 10 dose....
ABSTRACT From 1999, the NHS Ayrshire and Arran Health Board implemented an innovative nurse‐led collaborative care model for management of patients with prostate cancer (PC). This article describes presents results a local evaluation to assess its impact. The comprised retrospective audit service against national standards PC management, undertaken in 2012. Seventy‐one patients, who were under during June 2008, included. Patient staff satisfaction also assessed using questionnaires...
4506 Background: Lenvatinib (LEN), an oral tyrosine kinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, in combination with EVE had manageable toxicity antitumor activity a phase 1 mRCC trial (CCP 2013;73:181). This II, open-label, multicenter study compared LEN, EVE, LEN+EVE pts mRCC. Methods: Pts progressive clear cell following VEGF-targeted therapy were randomized 1:1:1 to LEN (24 mg/d), (10 or (18+5 mg/d) 28d cycles. The primary objective was progression-free survival (PFS) vs...
619 Background: There is a strong rationale for investigating MET and PD-L1 inhibition in metastatic papillary renal cancer (PRC). We previously reported response rates (RR) progression free survival (PFS) savolitinib (MET inhibitor) durvalumab (PD-L1 together. Here we report overall (OS) data available 12 months after the last patient was enrolled. Methods: This single arm phase I/II trial explores (1500mg Q4W) (600mg OD) together PRC, with 4wk run in. Treatment naïve or treated patients...
4511 Background: Savolitinib is a potent and selective MET inhibitor with activity in MET-driven papillary renal cancer (PRC). Durvalumab PD-L1 which has been tested combination savolitinib metastatic PRC response rates of 29% (12/41). Here we describe the efficacy this PRC. Methods: This single arm phase I/II trial explored durvalumab (1500mg Q4W) (600mg OD) together PRC, 4wk run in. Biomarker analysis results were compared responses to treatment as planned protocol. The presented here...
Elevated beta-HCG serum levels are usually an indication of pregnancy or pregnancy-related disorders, but can also be elevated in testis and germ cell tumors. HCG expression by osteosarcoma is a rare phenomenon, with few documented cases. CA-125 commonly used to monitor disease progression treatment response ovarian cancer. patients has not previously been documented.Elevated were observed female patient 57 years age metastatic during screening investigations prior participation phase I...
Abstract Background No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) progression-free survival (PFS) and overall (OS) patients with metastatic RCC randomised receive lenvatinib-plus-everolimus. Methods Of 40 tested, the 5 most strongly associated PFS (HGF, MIG, IL-18BP, IL-18, ANG-2) or OS (TIMP-1, M-CSF, ANG-2, VEGF) were used make...
Central venous catheter (CVC) insertion is commonly undertaken in the ICU. The use of ultrasound (US) to facilitate CVC standard and supported by guidelines. Because subclavian vein cannot be insonated where it underlies clavicle, its as a site now less common. axillary vein, however, can seen on US just distal placement at this gives result which functionally indistinguishable from CVC. We evaluated US-guided CVCs mechanically ventilated intensive care patients. Data were collected for 125...
3526 Background: E7080 is a potent inhibitor of the split-kinase family transmembrane growth factor receptors including VEGFRs 1 and 2, also potently inhibits FGFR-1 PDGFR-β tyrosine kinase activities. inhibited VEGF-driven umbilical vein endothelial cell proliferation tube formation in vitro, tumor H460 Colo205 mouse xenografts models vivo at doses 1–100mg/kg. Methods: The primary objective this study was to determine maximum tolerated dose (MTD) limiting toxicity (DLT) pts with advanced...